Antiretroviral Therapy-Induced Functional Modification of IgG4 and IgM Responses in HIV-1–Infected Individuals Screened by an Allosteric Biosensor

Abstract

We have explored the effect of antiretroviral drugs on the antiviral immune response in human immunodeficiency virus-1 (HIV-1)—infected patients by using an enzymatic immunosensor that detects epitope-modifying anti-gp41 antibodies. By this molecular sensing approach, we have identified an irreversible impact of drug administration on the functionality of IgG4 and IgM specific antibodies regarding the structural modification promoted on their target epitope. During the antiretroviral therapy, the prevalent induced fit promoted by IgM on the epitope was lost at the expense of that promoted by IgG4, suggesting alternative-ness in the neutralization potency of these antibody subpopulations. Because the particular drug composition of the antiretroviral treatment did not affect such immune shift, the obtained data strongly suggest that the drop in the viral load and the consequent lost of antigenemia are responsible for the functional adaptation observed in the humoral response. (Journal of Biomolecular Screening 2008:817-821)

Keywords

antiviral drug immunosensor HIV-1 humoral response gp41

References

Wei X. , Decker JM , Wang S. , Hui H. , Kappes JC , Wu X. , et al: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.

Poignard P. , Klasse PJ , Sattentau QJ : Antibody neutralization of HIV-1. Immunol Today 1996;17:239-246.

Kwong PD , Doyle ML , Casper DJ , Cicala C. , Leavitt SA , Majeed S. , et al: HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-682.

de Rosny E. , Vassell R. , Jiang S. , Kunert R. , Weiss CD : Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004;78:2627-2631.

Myszka DG , Sweet RW , Hensley P. , Brigham-Burke M. , Kwong PD , Hendrickson WA , et al: Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 2000;97:9026-9031.

Dhillon AK , Donners H. , Pantophlet R. , Johnson WE , Decker JM , Shaw GM , et al: Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors . J Virol 2007;81:6548-6562.

Adalid-Peralta L. , Grangeot-Keros L. , Rudent A. , Ngo-Giang-Huong N. , Krzysiek R. , Goujard C. , et al: Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med 2006 ;7:514-519.

Voltersvik P. , Albrektsen G. , Ulvestad E. , Dyrhol-Riise AM , Sorensen B. , Asjo B. : Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr 2003;34:358-367.

Ferraz RM , Vera A. , Aris A. , Villaverde A. : Insertional protein engineering for analytical molecular sensing. Microb Cell Fact 2006;5:15.

10.

Ferrer-Miralles N. , Feliu JX , Vandevuer S. , Müller A. , Cabrera-Crespo J. , Ortmans I. , et al: Engineering regulable Escherichia coli beta-galactosidases as biosensors for anti-HIV antibody detection in human sera. J Biol Chem 2001;276:40087-40095.

11.

Ferraz RM , Aris A. , Martinez MA , Villaverde A. : High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. Mol Immunol 2006;43:2119-2123.

12.

Miller JH : Experiments in Molecular Genetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1972.

13.

Sambrook J. , Fritsch E. , Maniatis T. : Molecular Cloning, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.